ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 171,47
0,70%
Dow Jones
42 123,15
1,30%
DAX
23 288,06
-0,45%
Brent Oil
70,575
0,60%
Bitcoin
85 579,95
3,46%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Oruka Therapeutics Inc (ORKA)

  7. Oruka Therapeutics Inc (ORKA) Actualités

ORKA

Oruka Therapeutics (ORKA)

Oruka Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ORKA
DateHeureSourceTitreSymboleSociété
12/03/202505h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ORKAOruka Therapeutics Inc
11/03/202500h00Edgar (US Regulatory)Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:ORKAOruka Therapeutics Inc
07/03/202514h30GlobeNewswire Inc.Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual MeetingNASDAQ:ORKAOruka Therapeutics Inc
06/03/202523h17Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:ORKAOruka Therapeutics Inc
06/03/202522h09GlobeNewswire Inc.Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateNASDAQ:ORKAOruka Therapeutics Inc
06/03/202522h02Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ORKAOruka Therapeutics Inc
28/02/202500h43Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ORKAOruka Therapeutics Inc
19/02/202513h00GlobeNewswire Inc.Oruka Therapeutics to Present at Multiple March Investor ConferencesNASDAQ:ORKAOruka Therapeutics Inc
05/02/202522h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORKAOruka Therapeutics Inc
24/01/202522h44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ORKAOruka Therapeutics Inc
19/12/202413h00GlobeNewswire Inc.Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 AntibodyNASDAQ:ORKAOruka Therapeutics Inc
18/12/202413h00GlobeNewswire Inc.Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)NASDAQ:ORKAOruka Therapeutics Inc
22/11/202400h30Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:ORKAOruka Therapeutics Inc
19/11/202414h00GlobeNewswire Inc.Oruka Therapeutics to Present at Piper Sandler’s 36th Annual Healthcare ConferenceNASDAQ:ORKAOruka Therapeutics Inc
15/11/202401h38Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ORKAOruka Therapeutics Inc
14/11/202423h20Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ORKAOruka Therapeutics Inc
14/11/202412h37Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:ORKAOruka Therapeutics Inc
13/11/202422h25GlobeNewswire Inc.Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:ORKAOruka Therapeutics Inc
13/11/202422h01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ORKAOruka Therapeutics Inc
04/11/202413h00GlobeNewswire Inc.Oruka Therapeutics to Present at Multiple November Investor ConferencesNASDAQ:ORKAOruka Therapeutics Inc
18/10/202422h11Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ORKAOruka Therapeutics Inc
25/09/202413h08GlobeNewswire Inc.Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology CongressNASDAQ:ORKAOruka Therapeutics Inc
12/09/202413h05GlobeNewswire Inc.Oruka Therapeutics Announces $200 Million Private PlacementNASDAQ:ORKAOruka Therapeutics Inc
12/09/202413h00GlobeNewswire Inc.Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19NASDAQ:ORKAOruka Therapeutics Inc
06/09/202423h08Edgar (US Regulatory)Form SC 13D - General Statement of Acquisition of Beneficial OwnershipNASDAQ:ORKAOruka Therapeutics Inc
06/09/202423h07Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ORKAOruka Therapeutics Inc
03/09/202413h00GlobeNewswire Inc.Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 MillionNASDAQ:ORKAOruka Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ORKA

Dernières Valeurs Consultées

BIT
UB0TDD
UniCredit Bank
AMEX
HDEF
Xtrackers MSCI EAFE High...
BIT
UC7PTM
Unicredit Bank
BIT
UC2US3
Unicredit Bank
USOTC
KYDKF
Kyudenko (PK)
USOTC
LVSDF
Lai Sun Development (PK)
NASDAQ
BND
Vanguard Total Bond Market
USOTC
MYIDF
Reklaim (PK)
BIT
UB261K
UniCredit Bank
USOTC
RRVCS
RSE Archive (GM)
NYSE
XPEV
XPeng
NYSE
CVNA
Carvana
BIT
UC5F1L
Unicredit Bank
AMEX
IEUR
MSCI Europe
USOTC
RARTS
RSE Archive (GM)
BIT
UC3X8G
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces